MECLON 10 OVULAR VAG 100+500MG

MECLON "100 MG + 500 MG OVULI"

active ingredients

A 2.4 g ovum contains: Active ingredients: Metronidazole 500 mg; Clotrimazole 100 mg. For the full list of excipients, see paragraph 6.1

Excellent

Excipients: Hydrophilic mixture of mono, tri-glycerides of saturated fatty acids.

Therapeutic indications

Cerviciti, cervico–vaginiti, vaginiti and vulvo–vaginiti from Trichomonas vaginalis even if associated with Candida or with bacterial component.

Contraindications

Hypersensitivity to active ingredients or any of the excipients.

Population

The optimal therapeutic scheme is as follows: 1 egg of MECLON in the vagina, 1 time a day.

Conservation

This medicine does not require any special condition for storage.

Warnings

Tell the patient to avoid contact with the eyes. The contemporary use of Metronidazole by mouth is subject to contraindications, side effects and warnings described for the above product. Avoid treatment with Meclon during the menstrual period. MECLON ovules should be used in early childhood under the direct control of the doctor and only in cases of actual need. With metronidazole-containing medicines for systemic use, severe hepatotoxicity/acute liver failure was reported, including cases with fatal outcome, with very quick start after treatment in patients with Cockayne syndrome. Therefore, in this metronidazole population it must be used after careful assessment of the risk-benefit ratio and only in the absence of alternative treatments. The analysis of liver function must be carried out just before the start of therapy, during and after the end of treatment, until the parameters of liver function are returned to the norm or the values will not be reached at the base. If the values of liver function analysis should increase significantly during treatment, the drug must be stopped. Patients suffering from Cockayne syndrome should be advised of the need to immediately report to the doctor any symptoms of potential liver injury and to stop treatment with metronidazole.

Interactions

None.

Effects

Given the low absorption by local application of the active ingredients Metronidazole and Clotrimazole, the adverse reactions found with the topical formulations are limited to: Immune system disorders: Notable (frequency cannot be defined on the basis of available data): hypersensitivity reactions. Pathologies of skin and subcutaneous tissue: Very rare (frequency)

Overdosing

No overdose symptoms have been described.

In pregnancy the product must be used only in case of actual need and under the direct control of the doctor.

Source: Farmadati